Targeting myeloid-derived suppressor cells with gemcitabine to enhance efficacy of adoptive cell therapy in bladder cancer

BackgroundNew therapeutics in development for bladder cancer need to address the recalcitrant nature of the disease. Intravesical adoptive cell therapy (ACT) with tumor infiltrating lymphocytes (TIL) can potentially induce durable responses in bladder cancer while maximizing T cells at the tumor sit...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Sarah Bazargan, Brittany Bunch, Awino Maureiq E. Ojwang‘, Jamie Blauvelt, Annick Landin, Johannes Ali, Dominique Abrahams, Cheryl Cox, Amy M. Hall, Matthew S. Beatty, Michael Poch, Katarzyna A. Rejniak, Shari Pilon-Thomas
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	Frontiers Media S.A. 2023-10-01
Reeks:	Frontiers in Immunology
Onderwerpen:	tumor infiltrating lymphocytes (TIL) adoptive cell therapy (ACT) non-muscle invasive bladder cancer (NMIBC) neoadjuvant gemcitabine lymphodepletion
Online toegang:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1275375/full
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!